MedPath
FDA Approval

Miglustat

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
March 17, 2025
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Miglustat(100 mg in 1 1)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

Navinta LLC

130443810

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Miglustat

Product Details

NDC Product Code
70710-2039
Application Number
ANDA219111
Marketing Category
ANDA (C73584)
Route of Administration
ORAL
Effective Date
March 17, 2025
MiglustatActive
Code: ADN3S497AZClass: ACTIBQuantity: 100 mg in 1 1
FERROSOFERRIC OXIDEInactive
Code: XM0M87F357Class: IACT
SHELLACInactive
Code: 46N107B71OClass: IACT
GELATINInactive
Code: 2G86QN327LClass: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30Class: IACT
POTASSIUM HYDROXIDEInactive
Code: WZH3C48M4TClass: IACT
POVIDONE K30Inactive
Code: U725QWY32XClass: IACT
SODIUM STARCH GLYCOLATE TYPE AInactive
Code: H8AV0SQX4DClass: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JPClass: IACT
© Copyright 2025. All Rights Reserved by MedPath